{
    "organizations": [],
    "uuid": "77e2b1692664fcaa14ac1d279e2d638505a5c560",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cosmo-pharmaceuticals-says-icc-arb/brief-cosmo-pharmaceuticals-says-icc-arbitral-tribunal-has-ruled-that-valeant-is-not-in-breach-of-uceris-license-agreement-idUSFWN1RP11T",
    "ord_in_thread": 0,
    "title": "BRIEF-Cosmo Pharmaceuticals Says ICC Arbitral Tribunal Has Ruled That Valeant Is Not In Breach Of Uceris License Agreement",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 12 (Reuters) - Cosmo Pharmaceuticals NV:\n* ANNOUNCES UNFAVOURABLE AWARD OF ARBITRAL TRIBUNAL IN RESPECT OF REQUEST TO TERMINATE UCERIS LICENSE AGREEMENT WITH VALEANT\n* ICC ARBITRAL TRIBUNAL HAS RULED THAT VALEANT IS NOT IN BREACH OF UCERIS LICENSE AGREEMENT, NOTWITHSTANDING COSMOâ€™S CLAIMS\n* COSMO WILL HAVE TO REIMBURSE VALEANT APPROX.$3 MLN IN LEGAL COST Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-13T02:09:00.000+03:00",
    "crawled": "2018-04-13T00:24:49.108+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "cosmo",
        "pharmaceutical",
        "nv",
        "announces",
        "unfavourable",
        "award",
        "arbitral",
        "tribunal",
        "respect",
        "request",
        "terminate",
        "uceris",
        "license",
        "agreement",
        "valeant",
        "icc",
        "arbitral",
        "tribunal",
        "ruled",
        "valeant",
        "breach",
        "uceris",
        "license",
        "agreement",
        "notwithstanding",
        "cosmo",
        "claim",
        "cosmo",
        "reimburse",
        "valeant",
        "mln",
        "legal",
        "cost",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}